Abstract: Daraxonrasib (RMC-6236) is an emerging, first-in-class, noncovalent pan-RAS(ON) inhibitor showing significant promise in the treatment of pancreatic ductal adenocarcinoma (PDAC). By forming a unique tri-complex with the intracellular chaperone cyclophilin A (CypA) and the active GTP-bound state of RAS, it effectively blocks downstream oncogenic signaling across multiple RAS isoforms and mutations. Early clinical trials demonstrate encouraging disease control and objective response rates in PDAC patients, alongside favorable tumor microenvironment remodeling. This review summarizes the pharmacological activity, molecular mechanism of action, structure-activity relationship, current limitations, and future therapeutic potential of daraxonrasib in PDAC based on recent literature.
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, representing the vast majority of pancreatic cancers, with a 5-year survival rate of under 10-12% [1][2]. A defining molecular hallmark of PDAC is the high prevalence of activating mutations in the KRAS oncogene, which occur in over 90% of cases (predominantly G12D, G12V, and G12R variants) [1][2]. Historically, RAS proteins were considered "undruggable" due to a lack of suitable binding pockets. While recent FDA-approved mutation-specific inhibitors (e.g., sotorasib and adagrasib) successfully target the KRAS G12C variant, they have limited applicability in PDAC because the G12C mutation accounts for only 1-3% of cases [1][2]. To address this critical therapeutic gap, broad-spectrum pan-RAS inhibitors have been developed. Daraxonrasib (RMC-6236) is a novel, multi-selective inhibitor targeting the active GTP-bound state of multiple RAS isoforms (KRAS, HRAS, NRAS), offering a promising therapeutic strategy to overcome the diverse mutational landscape of PDAC [1][2][3].
2. Pharmacological Activity
Daraxonrasib exhibits potent preclinical and clinical pharmacological activity against RAS-driven cancers. In animal models, it induced dose-dependent tumor regression across various KRAS mutations, including G12D, G12V, and G12C [1]. Pharmacokinetically, RMC-6236 accumulates specifically in tumor tissues, reaching concentrations 3 to 7 times higher than in the blood, and exhibits slower clearance from tumors compared to other tissues [3]. Notably, it can cross the blood-brain barrier (BBB) in a dose-dependent manner, expanding its potential for treating patients with brain metastases [2][3].
In early-phase clinical trials (e.g., NCT05379985), RMC-6236 demonstrated meaningful clinical activity. In PDAC patients, it achieved an objective response rate (ORR) of 20% and a disease control rate (DCR) of 87% [2]. The median progression-free survival (mPFS) was reported as 8.1 months for patients with KRAS G12X mutations and 7.6 months for broadly RAS-mutant tumors [1]. Furthermore, RMC-6236 favorably remodels the tumor microenvironment (TME). It enhances the infiltration of CD4+ and CD8+ T cells, increases MHC class II expression on tumor cells, and reduces immunosuppressive populations such as M2-like macrophages and myeloid-derived suppressor cells (MDSCs), thereby alleviating immune cell exclusion [2].
3. Molecular Mechanism of Action
Unlike traditional covalent inhibitors that target the inactive GDP-bound RAS(OFF) state, daraxonrasib is a nonsteroidal, noncovalent pan-RAS(ON) inhibitor [1][2]. It specifically binds to the active, GTP-bound state of all RAS isoforms (KRAS, HRAS, NRAS), encompassing both mutant and wild-type forms [2]. Mechanistically, RMC-6236 acts as a molecular glue, recruiting the intracellular chaperone protein cyclophilin A (CypA) to form a nonproductive ternary complex (tri-complex) with RAS-GTP [1][2][3]. This tri-complex locks RAS in a conformationally restricted, signaling-incompetent state, sterically preventing it from interacting with downstream effectors such as RAF kinases, PI3K, and RAL-GDS [2][3]. By neutralizing the oncogenic signal at its active state rather than blocking activation, daraxonrasib effectively and durably silences downstream MAPK and PI3K/AKT signaling pathways [2].
4. Structure-Activity Relationship (SAR)
The structural basis of daraxonrasib's activity relies on its ability to occupy the switch II pocket (SII-P) of the RAS protein while simultaneously engaging CypA [2]. RMC-6236 binds to CypA with high affinity (kd = 55.3 nmol/L) [3]. Once this binary complex is formed, the remodeled CypA surface creates a high-affinity interface for the GTP-bound state of RAS variants. The resulting RMC-6236–CypA complex binds to various KRAS forms with distinct affinities: KRAS G12D (kd = 131 nmol/L), KRAS G12V (kd = 364 nmol/L), and wild-type KRAS (kd = 154 nmol/L) [3]. This structural mechanism reduces the dynamic flexibility of RAS-GTP necessary for effector binding, enabling broad-spectrum inhibition across multiple oncogenic mutations while maintaining a functional tri-complex [2].
5. Current Limitations
Despite its promise, the clinical application of daraxonrasib faces several limitations. Safety and tolerability are primary concerns, given the essential role of wild-type RAS signaling in normal tissue homeostasis [2]. Common adverse events (AEs) include rash, diarrhea, nausea, vomiting, stomatitis, fatigue, paronychia, mucosal inflammation, and peripheral edema [1]. While most AEs are manageable (Grade 1-2), Grade 3 events (rash, nausea, diarrhea) led to treatment discontinuation in approximately 5% of patients. Rare Grade 4 events, such as large intestine perforation at the site of invasive PDAC, have also been reported (1% of patients) [2].
Additionally, acquired resistance remains a significant challenge. Cancer cells can bypass pan-RAS inhibition through compensatory mechanisms, such as the activation of the YAP/TAZ-TEAD transcriptional complex, focal amplification of the MYC oncogene, epithelial-mesenchymal transition (EMT), and receptor tyrosine kinase (RTK) hyperactivation (e.g., EGFR feedback loops) [2]. The lack of validated predictive biomarkers for patient selection also complicates its optimal clinical deployment [2].
6. Future Perspectives
The future development of daraxonrasib in PDAC is focused on optimizing dosing, confirming efficacy in larger cohorts, and exploring rational combination therapies. Several clinical trials are currently underway, including the Phase III RASolute 302 trial (NCT06625320), which compares RMC-6236 to standard-of-care chemotherapy in previously treated metastatic PDAC [1][2]. To counteract resistance mechanisms, combination strategies are being actively investigated. Pairing RMC-6236 with YAP-TEAD inhibitors (e.g., IAG933) or immune checkpoint inhibitors (e.g., anti-PD-1) shows potential to suppress bypass signaling and leverage the drug's immune-activating TME effects [2]. Future research must also prioritize the identification of predictive biomarkers, such as MHC-II expression and T-cell clonality, to better select patients who will benefit from pan-RAS(ON) inhibition [2].
